10 results about "Platelet factor" patented technology

This invention relates to the field of biotechnology, specifically to a TruC-T cell that secretes and expresses IL-7 and PF4 to enhance anti-tumor activity and targets uPAR, and its application. Interleukin-7 (IL-7) can effectively promote the development, survival, and proliferation of T cells, while platelet factor 4 (PF4 / CXCL4) can regulate the immune response and chemotactically attract leukocytes to specific sites; the synergistic effect of the two can enhance the anti-tumor function and persistence of T cells. Meanwhile, urokinase-type plasminogen activator receptor (uPAR) is highly expressed in various solid tumors and hematological malignancies, making it an ideal target for tumor therapy; TruC-T cells targeting uPAR can precisely act on tumor tissue, and combined with the immune-enhancing effects of IL-7 and PF4, can significantly improve the efficacy of anti-tumor immune responses, prolong the duration of therapeutic effects, and reduce tumor recurrence.

The invention relates to the field of biological medicines, in particular to application of a platelet factor 4 in preparation of a medicine for treating and / or preventing senile deafness. Experimental results show that PF4 not only does not aggravate hearing loss of a subject and structural damage of cochlea tissues, but also can reduce an auditory induction threshold of the subject, so that the hearing loss is obviously improved, and the effect of improving senile deafness is achieved. The PF4 can be used as a medicine for treating and / or preventing the senile deafness, and the occurrence and development of the senile deafness can be effectively regulated.

A composition for suppressing the accumulation of helper T1 regulatory T cells in tumors, said composition containing an antibody that recognizes platelet factor 4 proteins as an active component. A drug composition for the treatment or prevention of cancer.

The present disclosure relates to reagents, kits, and methods for the detection of anti-PF4 antibodies and the diagnosis of non-heparin-induced thrombotic events including vaccine-induced thrombotic thrombocytopenia. The methods provided by the present disclosure include (i) contacting a whole blood, plasma, or serum sample obtained from a subject with a reagent comprising (a) a binding molecule selected from the group consisting of platelet factor 4 protein (PF4), a fragment of PF4 capable of binding to an anti-PF4 antibody, and an anti-idiotype antibody of an anti-platelet factor 4 antibody (anti-PF4 antibody), and (b) a solid support, wherein the binding molecule (a) is covalently bound to the surface of the solid support (b), and the binding molecule (a) does not contain heparin or a heparin surrogate, and (ii) analyzing the sample to detect a complex formed by the reagent and the anti-PF4 antibody, wherein detecting the complex indicates that the sample contains an anti-PF4 antibody, and includes.

This invention relates to a heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity, its preparation method, and its application, belonging to the field of biomedical technology. The heparin anticoagulant oligosaccharide with low thrombocytopenia-inducing activity comprises an AT-binding sequence and a -GlcNS(6S)-GlcA2S- or -GlcNS(6S)-IdoA2S- linker sequence, specifically heparin anticoagulant dodecanosaccharide 12I-2, heparin anticoagulant dodecanosaccharide 12G-1, or heparin anticoagulant dodecanosaccharide 12G-2. This invention also provides methods for preparing heparin anticoagulant dodecanosaccharides 12I-2, 12G-1, and 12G-2, and their applications in the preparation of safe and effective anticoagulant and antithrombotic drugs. The heparin anticoagulant oligosaccharide designed in this invention is a specific dodecanoic acid molecule. By optimizing its sugar chain length, key structural domains and spatial conformation, its ability to form pathogenic H / PF4 complexes with platelet factor 4 (PF4) is weakened to the greatest extent. In clinical anticoagulation applications, it has a significant safety advantage in reducing the incidence of HIT and related fatal thrombosis (HITT).

Provided is a recombinant fibronectin fusion protein comprising a recombinant fibronectin mutant and platelet factor 4, wherein the recombinant fibronectin fusion protein has an amino acid sequence as set forth in SEQ ID NO: 3 or SEQ ID NO: 4, and a molecular weight of not more than 90 kDa. The recombinant fibronectin fusion protein exhibits good solubility, has a simple preparation process, and is conveniently purified. The recombinant fibronectin fusion protein comprises a new recombinant fibronectin, and can inhibit inflammation during wound healing, and promote cutaneous wound healing in mice. When platelet factor 4 is fused to the N-terminus of the recombinant fibronectin mutant, cell proliferation activity can be significantly and effectively enhanced.

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange / hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration / diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

The disclosure refers to reagents, kits and methods for detecting anti-PF4 antibodies and diagnosing thrombotic events not induced by heparin, including vaccine-induced thrombotic thrombocytopenia. The method provided by the disclosure comprises: (i) contacting whole blood. plasma or serum sample obtained from a subject with a reagent comprising: (a) a binding molecule selected from the group consisting of platelet factor 4 protein (PF4), a fragment of PF4 which can bind anti-PF4 antibodies, and an anti-idiotype antibody of anti-platelet factor 4 antibodies (anti-PF4 antibodies); and (b) a solid support, wherein the binding molecule (a) is covalently bound to the surface of the solid support (b), and wherein the binding molecule (a) does not include heparin or a heparin surrogate, and (ii) analysing the sample to detect a complex formed by the reagent and the anti-PF4 antibodies, wherein detecting the complex is indicative of the sample containing anti-PF4 antibodies.

The invention relates to the technical field of biomedicine, in particular to application of a platelet factor 4 in preparation of a medicine for treating acute ischemic stroke. The platelet factor 4 can be used for remarkably relieving neurological impairment in the acute stage of ischemic stroke and reducing the infarct volume. For the early intervention of the acute ischemic stroke, a good treatment potential is shown, and a new drug target and a treatment strategy are provided for the treatment of the acute ischemic stroke.

The present application relates to the use of platelet factor 4 in the preparation of a drug for treating or preventing Candida albicans infection, platelet factor 4 acts on macrophage CXCR3 receptor, antagonizes Candida albicans induced macrophage PANoptosis, thereby reducing the damage of Candida albicans to macrophages, maintaining the survival and normal function of macrophages, enhancing the clearance ability of the body to Candida albicans, reducing the inflammatory response caused by infection, reducing pathological damage, and different from the treatment mechanism of traditional antifungal drugs, the present application does not directly act on fungi, which helps to reduce the formation of drug-resistant strains and the toxic side effects such as liver toxicity and kidney toxicity caused by antifungal drugs, and can provide a more optimal new treatment mode for clinical Candida albicans infection.